» Articles » PMID: 31496618

Treatment of Hepatocellular Carcinoma in Patients with Portal Vein Tumor Thrombosis: Beyond the Known Frontiers

Overview
Specialty Gastroenterology
Date 2019 Sep 10
PMID 31496618
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma is one of the most frequent malignant tumors worldwide: Portal vein tumor thrombosis (PVTT) occurs in about 35%-50% of patients and represents a strong negative prognostic factor, due to the increased risk of tumor spread into the bloodstream, leading to a high recurrence risk. For this reason, it is a contraindication to liver transplantation and in several prognostic scores sorafenib represents its standard of care, due to its antiangiogenetic action, although it can grant only a poor prolongation of life expectancy. Recent scientific evidences lead to consider PVTT as a complex anatomical and clinical condition, including a wide range of patients with different prognosis and new treatment possibilities according to the degree of portal system involvement, tumor biological aggressiveness, complications caused by portal hypertension, patient's clinical features and tolerance to antineoplastic treatments. The median survival has been reported to range between 2.7 and 4 mo in absence of therapy, but it can vary from 5 mo to 5 years, thus depicting an extremely variable scenario. For this reason, it is extremely important to focus on the most adequate strategy to be applied to each group of PVTT patients.

Citing Articles

Clinical significance of surgical resection for hepatocellular carcinoma with portal vein invasion: a nationwide cohort study.

Jo H, Park P, Yu Y, Choi Y, Yu S, Kim D Hepatobiliary Surg Nutr. 2024; 13(5):814-823.

PMID: 39507744 PMC: 11534781. DOI: 10.21037/hbsn-23-578.


Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma.

Hao K, Paik A, Han L, Makary M World J Radiol. 2024; 16(10):512-527.

PMID: 39494134 PMC: 11525828. DOI: 10.4329/wjr.v16.i10.512.


The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma.

Tang X, Chen J, Peng W, Yang Z, Hu L, Ye Z Immunotargets Ther. 2024; 13:559-569.

PMID: 39478940 PMC: 11524013. DOI: 10.2147/ITT.S478685.


The Molecular Mechanisms of Portal Vein Thrombosis in Hepatocellular Carcinoma.

Galasso L, Cerrito L, Termite F, Mignini I, Esposto G, Borriello R Cancers (Basel). 2024; 16(19).

PMID: 39409869 PMC: 11482560. DOI: 10.3390/cancers16193247.


Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study.

Tan H, Liu S, Zheng J, Liu H, Liu Y, Dai G Abdom Radiol (NY). 2024; 50(3):1320-1329.

PMID: 39392475 DOI: 10.1007/s00261-024-04620-1.


References
1.
Memon K, Kulik L, Lewandowski R, Mulcahy M, Benson A, Ganger D . Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2012; 58(1):73-80. PMC: 3527660. DOI: 10.1016/j.jhep.2012.09.003. View

2.
Zhang Y, Le Y, Wei W, Zou R, Wang J, OuYang H . Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis. Oncotarget. 2016; 7(25):38845-38856. PMC: 5122434. DOI: 10.18632/oncotarget.8642. View

3.
Ajit Y, Sudarsan H, Saumya G, Abhishek A, Navneet R, Piyush R . Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis: a perspective on survival. Oman Med J. 2015; 29(6):430-6. PMC: 4289489. DOI: 10.5001/omj.2014.114. View

4.
Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K . Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol. 2009; 44(5):492-502. DOI: 10.1007/s00535-009-0033-y. View

5.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View